Osseon Therapeutics, a biomedical device company, has received a notice of patent allowance for its spinal vertebral compression fracture (VCF) technology.
California-based Osseon has 13 additional patent applications pending in the US and throughout the world for related spinal therapies and devices. The lead inventor for the inaugural patent is Dr King Liu, one of the three founders of Osseon.
Osseon has been marketing its FDA approved first generation ‘Osseoplasty’ systems since February, 2009. The Osseon devices have received CE mark in November 2009 and the company began marketing the product line in Europe in February 2010.
According to Osseon, the Osseoplasty procedure has been performed in over 900 patients in the US and Europe.
John Stalcup, CEO of Osseon, said: “This initial patent allowance for Osseon’s spinal VCF technology is a major milestone for the company’s intellectual property pursuits.
“We anticipate receiving a number of additional patents in the future on various aspects of the Osseoflex steerable and curvable needle and the novel methods for bone cement delivery, which enable a safe, effective, and minimally invasive approach for spine disease treatment.”